2-chloro-5-(3-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl)pyridine | 1192886-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-5-(3-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl)pyridine
• 英文别名: 4-(2-chloropyridin-5-yl)-3-(3-methoxy-5-methylphenyl)-1H-pyrazol；2-chloro-5-[5-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl]pyridine
• CAS: 1192886-16-0
• 化学式: C₁₆H₁₄ClN₃O
• 分子量: 299.76
• InChiKey: ZSHTZVXTCNHIJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-5-(3-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl)pyridine 在 三氟二甲基硫醚络合物 、 potassium carbonate 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 40.0h， 生成 2-(4-(6-(2-acetylphenyl)pyridin-3-yl)-3-(3-hydroxy-5-methylphenyl)-1H-pyrazol-1-yl)acetonitrile
  参考文献：
  名称：

  PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE

  摘要：

  本文披露了新型吡唑化合物，其药用盐，其制备方法，以及作为抗癌剂的用途。

  公开号：

  US20110015395A1
• 作为产物：
  描述：

  3-羟基-5-甲基苯甲酸 在 4-二甲氨基吡啶 potassium carbonate 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 46.0h， 生成 2-chloro-5-(3-(3-methoxy-5-methylphenyl)-1H-pyrazol-4-yl)pyridine
  参考文献：
  名称：

  PYRAZOLE COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST ROS KINASE

  摘要：

  本文披露了新型吡唑化合物，其药用盐，其制备方法，以及作为抗癌剂的用途。

  公开号：

  US20110015395A1

文献信息

• Pyrazole compounds with inhibitory activity against ROS kinase
  申请人：Korea Institute of Science and Technology

  公开号：US08273880B2

  公开（公告）日：2012-09-25

  Disclosed herein are novel pyrazole compounds, pharmaceutically acceptable salts thereof, a method for preparing the same, and uses thereof as anticancer agents.

  本文披露了一种新型吡唑化合物、其药学上可接受的盐的制备方法，以及其作为抗癌剂的用途。
• Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors
  作者：Ibrahim M. El-Deeb、Byung Sun Park、Su Jin Jung、Kyung Ho Yoo、Chang-Hyun Oh、Seung Joo Cho、Dong Keun Han、Jae Yeol Lee、So Ha Lee

  DOI：10.1016/j.bmcl.2009.08.029

  日期：2009.10

  A series of rationally designed ROS1 tyrosine kinase inhibitors was synthesized and screened. Compound 12b has showed good potency with IC50 value of 209 nM, which is comparable with that of the reference lead compound 1. Molecular modeling studies have been performed, that is, a homology model for ROS1 was built, and the screened inhibitors were docked into its major identified binding site. The docked poses along with the activity data have revealed a group of the essential features for activity. Overall, simplification of the lead compound 1 into compound 12b has maintained the activity, while facilitated the synthetic advantages. A molecular interaction model for ROS1 kinase and inhibitors has been proposed. (C) 2009 Elsevier Ltd. All rights reserved.
• Design and synthesis of new potent anticancer pyrazoles with high FLT3 kinase inhibitory selectivity
  作者：Ibrahim Mustafa El-Deeb、So Ha Lee

  DOI：10.1016/j.bmc.2010.04.029

  日期：2010.6.1

  A new series of 1H- and 2H-pyrazole derivatives (35 final compounds) has been designed and synthesized in this study. A selected group (13 compounds) was then tested over a panel of 60 cancer cell lines at a single dose concentration of 10 mu M. At this concentration, six compounds have showed moderate to strong mean inhibitions, and were further tested at five-dose testing mode to determine their IC(50) over the 60 cell lines. The IC(50) values of the tested compounds indicated high potency (as for compound 10f) as well as high efficacy (as for compound 11e). Accordingly, compound 10f was then tested at a single dose concentration of 10 mu M over a panel of 54 kinases to determine its kinase inhibitory pro. le. The compound has showed good selectivity towards FLT3 kinase, associated with a moderate potency, with an IC(50) value of 1.74 mu M. (C) 2010 Elsevier Ltd. All rights reserved.
• US8273880B2
  申请人：——

  公开号：US8273880B2

  公开（公告）日：2012-09-25